ALVAC-gp160/rgp120 HIV vaccine: Phase I

Johns Hopkins researchers published in The Journal of Infectious Diseases results from a Phase I safety and immunogenicity trial showing an enhanced antibody and cellular immune response to the combination of two HIV antigens. A total of 131 patients who were not infected with HIV received a canarypox vector expressing the HIV gp160 antigen (ALVAC-gp160), recombinant HIV gp120 protein (rgp120), a control vaccine, or the combination of ALVAC-160 and rgp120. Prior patient immunity to vaccinia virus (related to the canarypox virus) did not affect response to the HIV vaccine, nor did dose of the ALVAC vector affect response. ...